Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Conditions : Relapsed or Refractory Multiple Myeloma (RRMM) Interventions : Drug: YKST02 Sponsors : Excyte Biopharma Ltd Not yet recruiting
Read the full article16h agoen
You might also wanna read
<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>
Pharmacy Times·1d ago
<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>
Pharmacy Times·1d ago
<![CDATA[Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings]]>
CancerNetwork·4h ago
<![CDATA[Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study]]>
CancerNetwork·4h ago
<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>
Pharmacy Times·1h ago
<![CDATA[How Are CELMoDs Reshaping Treatment in Multiple Myeloma?]]>
CancerNetwork·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.